Data & Intelligence

Impact Case Study: Biosensors International Group

Hony Capital invested US$200 million for a 24.8% stake in the company.

  • Company Headquarters: Singapore
  • Business focus: Medical devices


  • As a financial backer and strategic local partner, Hony Capital helped Biosensors align interests amongst all shareholders in its Chinese joint venture, JW Medical, and expand its business in China

  • Between FY 2010 and FY 2012, Biosensors grew revenues from SGD147 million to SGD369 million, a CAGR of 59%, while increasing its gross margins by 7.7 percentage points

  • Biosensors has grown its business in China from 9% of its total revenue in FY 2011 to 21% of its total revenue in FY 2012

  • Biosensors’s pioneering drug-eluting technology has helped the company to penetrate markets in 70 countries


As a Founding Member Firm of EMPEA , I am proud of what the organization achieved. I look forward to playing an active role on the Board of Directors as we enter our next phase.

Drew Guff | Managing Director and Founding Partner, Siguler Guff & Company

I’m honored to join fellow industry pioneers in the leadership of an unparalleled network, filled with first movers, shaping the future of industries and communities.

Dr. Andrew Kuper | Founder and CEO, LeapFrog Investments

EMPEA's market and industry intelligence opens doors to new sources of capital.  I look forward to the future success of EMPEA and its members

Torbjorn Caesar | Senior Partner, Actis

While there are certainly challenges for the industry, the opportunities abound in our target markets and globally, making a global association like EMPEA more relevant than ever.

Drew Guff | Managing Director & Founding Partner, Siguler Guff & Company

The developed markets have no equivalent to the role EMPEA is playing as a convener and source of trusted information in the emerging markets.

David Rubenstein | Co-Founder and Managing Director, The Carlyle Group